Demographic characteristics according to remission status (CR1 vs CR2+) and conditioning regimen for patients in CR1
| Characteristic . | All (N = 81) . | CR1 MAC (n = 26) . | CR1 NMAC (n = 43) . | P . | CR2+ (n = 12) . |
|---|---|---|---|---|---|
| Female sex, n (%) | 46 (56.8) | 19 (73.1) | 21 (48.8) | .07 | 6 (50) |
| Median age (range), y | 49.2 (21.0-71.9) | 46.1 (21-63.1) | 50.4 (26.7-71.9) | .1 | 51.3 (29.5-65.5) |
| Age >60 y, n (%) | 17 (20.1) | 2 (7.7) | 12 (27.9) | .06 | 3 (25) |
| Median WBC at diagnosis (range), ×103/μL | 18 (1-386) | 19 (2-300) | 18 (1-386) | .79 | |
| Prior CNS involvement, n (%) | 7 (8.6) | 0 (0) | 2 (4.7) | 5 (41.7) | |
| Transcript at diagnosis, n (%) | |||||
| p190 alone | 49 (60.4) | 16 (61.5) | 25 (58.1) | .47 | 8 (66.7) |
| p210 alone | 12 (14.8) | 2 (7.7) | 8 (18.6) | 2 (16.7) | |
| Other | 3 (3.7) | 2 (7.7) | 1 (2.3) | 0 | |
| Unknown | 17 (21.0) | 6 (23.0) | 9 (20.9) | 2 (16.7) | |
| TKI at diagnosis, n (%) | .07 | ||||
| Imatinib | 15 (57.7) | 13 (30.2) | |||
| Dasatinib | 8 (30.7) | 25 (58.1) | |||
| Nilotinib | 3 (11.5) | 5 (11.6) | |||
| HCT-CI score, n (%)* | .001 | ||||
| 0 (low) | 25 (31.6) | 15 (57.5) | 7 (17.1) | 3 (25) | |
| 1-2 (intermediate) | 30 (38.0) | 8 (30.8) | 16 (39.0) | 6 (50) | |
| 3+ (high) | 24 (30.4) | 3 (11.5) | 18 (43.9) | 3 (25) | |
| Median KPS (range) | 90 (80-100) | 90 (90-100) | 90 (80-100) | .1 | 90 (80-100) |
| Prior allogeneic transplant, n (%) | 6 (50) | ||||
| Median duration of CR1 (range), mo | 16 (5.9-50.5) | ||||
| CR1 duration <1 y, n (%) | 5 (41.7) |
| Characteristic . | All (N = 81) . | CR1 MAC (n = 26) . | CR1 NMAC (n = 43) . | P . | CR2+ (n = 12) . |
|---|---|---|---|---|---|
| Female sex, n (%) | 46 (56.8) | 19 (73.1) | 21 (48.8) | .07 | 6 (50) |
| Median age (range), y | 49.2 (21.0-71.9) | 46.1 (21-63.1) | 50.4 (26.7-71.9) | .1 | 51.3 (29.5-65.5) |
| Age >60 y, n (%) | 17 (20.1) | 2 (7.7) | 12 (27.9) | .06 | 3 (25) |
| Median WBC at diagnosis (range), ×103/μL | 18 (1-386) | 19 (2-300) | 18 (1-386) | .79 | |
| Prior CNS involvement, n (%) | 7 (8.6) | 0 (0) | 2 (4.7) | 5 (41.7) | |
| Transcript at diagnosis, n (%) | |||||
| p190 alone | 49 (60.4) | 16 (61.5) | 25 (58.1) | .47 | 8 (66.7) |
| p210 alone | 12 (14.8) | 2 (7.7) | 8 (18.6) | 2 (16.7) | |
| Other | 3 (3.7) | 2 (7.7) | 1 (2.3) | 0 | |
| Unknown | 17 (21.0) | 6 (23.0) | 9 (20.9) | 2 (16.7) | |
| TKI at diagnosis, n (%) | .07 | ||||
| Imatinib | 15 (57.7) | 13 (30.2) | |||
| Dasatinib | 8 (30.7) | 25 (58.1) | |||
| Nilotinib | 3 (11.5) | 5 (11.6) | |||
| HCT-CI score, n (%)* | .001 | ||||
| 0 (low) | 25 (31.6) | 15 (57.5) | 7 (17.1) | 3 (25) | |
| 1-2 (intermediate) | 30 (38.0) | 8 (30.8) | 16 (39.0) | 6 (50) | |
| 3+ (high) | 24 (30.4) | 3 (11.5) | 18 (43.9) | 3 (25) | |
| Median KPS (range) | 90 (80-100) | 90 (90-100) | 90 (80-100) | .1 | 90 (80-100) |
| Prior allogeneic transplant, n (%) | 6 (50) | ||||
| Median duration of CR1 (range), mo | 16 (5.9-50.5) | ||||
| CR1 duration <1 y, n (%) | 5 (41.7) |
CNS, central nervous system; HCT-CI, hematopoietic cell transplantation–specific comorbidity index; KPS, Karnofsky performance status.
Pulmonary function test results were unavailable for 2 patients who were omitted from analysis for HCT-CI.